India’s pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceutical Industries and Aurobindo Pharma are likely to report good growth. In contrast, Dr Reddy’s Laboratories and Lupin may face challenges due to increased competition and a high base. Pricing pressure and elevated raw material costs are also expected to impact overall performance.
More in Economy
US stocks today: US stocks gain as healthcare stocks hit record high, oil prices fall
October 20, 2026
OYO-parent PRISM to nearly halve IPO fresh issue size to up to Rs 3,350 cr: Sources
October 20, 2026
US Stocks: GE Aerospace raises 2026 profit forecast as services strength drives growth
October 20, 2026
US Stocks: GM's core profit rises 22% on strength of pickup-truck business
October 20, 2026
Jio IPO opens tomorrow: How can investors maximise allotment chances under Rs 2,500 crore RIL shareholders quota
October 20, 2026
WhatsApp stock tips: Nithin Kamath warns of more pump-and-dump schemes as ED freezes accounts worth Rs 200 crore
October 20, 2026
Latest News
A 1930 law, 50% tariffs and a new lawsuit: Trump faces fresh challenge over Canada duties
October 20, 2026
Delhi airport traffic hits record first-half high with 38.5 million passengers, eyeing expansion
October 20, 2026
Delhi AQI to slip into 'poor' category from Wednesday, pollution levels to rise
October 20, 2026
Marco Rubio in India: Can US biz diplomacy ease Trump tensions over tariffs, Russian oil and bring trade deal closer?
October 20, 2026
Michael Bloomberg backs Democrats with $80 million but remains wary of party’s leftward shift: Report
October 20, 2026
US, India ‘very, very close’ to trade deal, says Rubio
October 20, 2026